NCT04939844: Phase 2: REST - Replacing Steroids in the Transplant Ineligble (REST)

REST

NCT04939844: Phase 2: REST - Replacing Steroids in the Transplant Ineligble (REST)

Newly diagnosed multiple myeloma patients ineligible for HD-ASCT will be included in the study. All participants will receive isatuximab in combination with bortezomib, lenalidomide and minimal dexamethasone until disease progression. The primary objective of this study is the MRD negativity rate during and/or after first 18 cycles of study treatment.

Sponsor

Oslo University Hospital

Collaborators

Nordic Myeloma Study Group

St. Olavs Hospital

Helse Stavanger HF

Information provided by (Responsible Party)

Fredrik Hellem Schjesvold, Oslo University Hospital

Location

Norway

---

ClinicalTrials.gov Identifier: NCT04939844

Official Title: Isatuximab in Combination With Bortezomib and Lenalidomide With Minimal Dexamethasone in Transplant-ineligible Multiple Myeloma

First Posted: June 25, 2021

Click here for details on ClinicalTrials.gov

---

Drug: Isatuximab, bortezomib, lenalidomide, dexamethasone

---

Location

Europe

Norway